Search

Your search keyword '"Bielorai, Bella"' showing total 279 results
Start Over Author "Bielorai, Bella"
279 results on '"Bielorai, Bella"'

1. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Author

Wu, Jen-Hao, Pennesi, Edoardo, Bautista, Francisco, Garrett, May, Fukuhara, Kei, Brivio, Erica, Ammerlaan, Anneke C. J., Locatelli, Franco, van der Sluis, Inge M., Rossig, Claudia, Chen-Santel, Christiane, Bielorai, Bella, Petit, Arnaud, Starý, Jan, Díaz-de-Heredia, Cristina, Rives, Susana, O’Marcaigh, Aengus, Rizzari, Carmelo, Engstler, Gernot, Nysom, Karsten, Rubio-San-Simón, Alba, Bruno, Benedicte, Bertrand, Yves, Brethon, Benoît, Rialland, Fanny, Plat, Geneviève, Dirksen, Uta, Sramkova, Lucie, Zwaan, C. Michel, and Huitema, Alwin D. R.

Published
2024
Full Text
View/download PDF

3. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study

Author

Jacoby, Elad, Ghorashian, Sara, Vormoor, Britta, De Moerloose, Barbara, Bodmer, Nicole, Molostova, Olga, Yanir, Asaf D, Buechner, Jochen, Elhasid, Ronit, Bielorai, Bella, Rogosic, Srdan, Dourthe, Marie-Emilie, Maschan, Michael, Rossig, Claudia, Toren, Amos, von Stackelberg, Arend, Locatelli, Franco, Bader, Peter, Zimmermann, Martin, Bourquin, Jean Pierre, and Baruchel, Andre

Published
2022
Full Text
View/download PDF

4. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Author

Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H. J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J. C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, and Zwaan, Christian M.

Published
2022
Full Text
View/download PDF

5. Genetic backgrounds and clinical characteristics of congenital neutropenias in Israel

Author

Yeshareem, Lital, primary, Yacobovich, Joanne, additional, Lebel, Asaf, additional, Noy‐Lotan, Sharon, additional, Dgany, Orly, additional, Krasnov, Tanya, additional, Berger Pinto, Galit, additional, Oniashvili, Nino, additional, Mardoukh, Jacques, additional, Bielorai, Bella, additional, Laor, Ruth, additional, Mandel‐Shorer, Noa, additional, Ben Barak, Ayelet, additional, Levin, Carina, additional, Asleh, Mahdi, additional, Miskin, Hagit, additional, Revel‐Vilk, Shoshana, additional, Levin, Dror, additional, Benish, Marganit, additional, Zuckerman, Tsila, additional, Wolach, Ofir, additional, Pazgal, Idit, additional, Brik Simon, Dafna, additional, Gilad, Oded, additional, Yanir, Asaf David, additional, Goldberg, Tracie Alison, additional, Izraeli, Shai, additional, Tamary, Hannah, additional, and Steinberg‐Shemer, Orna, additional

Published
2024
Full Text
View/download PDF

8. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Author

Brivio, Erica, Locatelli, Franco, Lopez-Yurda, Marta, Malone, Andrea, Díaz-de-Heredia, Cristina, Bielorai, Bella, Rossig, Claudia, van der Velden, Vincent H.J., Ammerlaan, Anneke C.J., Thano, Adriana, van der Sluis, Inge M., den Boer, Monique L., Chen, Ying, Sleight, Barbara, Brethon, Benoit, Nysom, Karsten, Sramkova, Lucie, Øra, Ingrid, Vinti, Luciana, Chen-Santel, Christiane, and Zwaan, Christian Michel

Published
2021
Full Text
View/download PDF

9. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Author

Apotheek O&O&O, Cancer, Wu, Jen Hao, Pennesi, Edoardo, Bautista, Francisco, Garrett, May, Fukuhara, Kei, Brivio, Erica, Ammerlaan, Anneke C.J., Locatelli, Franco, van der Sluis, Inge M., Rossig, Claudia, Chen-Santel, Christiane, Bielorai, Bella, Petit, Arnaud, Starý, Jan, Díaz-de-Heredia, Cristina, Rives, Susana, O’Marcaigh, Aengus, Rizzari, Carmelo, Engstler, Gernot, Nysom, Karsten, Rubio-San-Simón, Alba, Bruno, Benedicte, Bertrand, Yves, Brethon, Benoît, Rialland, Fanny, Plat, Geneviève, Dirksen, Uta, Sramkova, Lucie, Zwaan, C. Michel, Huitema, Alwin D.R., Apotheek O&O&O, Cancer, Wu, Jen Hao, Pennesi, Edoardo, Bautista, Francisco, Garrett, May, Fukuhara, Kei, Brivio, Erica, Ammerlaan, Anneke C.J., Locatelli, Franco, van der Sluis, Inge M., Rossig, Claudia, Chen-Santel, Christiane, Bielorai, Bella, Petit, Arnaud, Starý, Jan, Díaz-de-Heredia, Cristina, Rives, Susana, O’Marcaigh, Aengus, Rizzari, Carmelo, Engstler, Gernot, Nysom, Karsten, Rubio-San-Simón, Alba, Bruno, Benedicte, Bertrand, Yves, Brethon, Benoît, Rialland, Fanny, Plat, Geneviève, Dirksen, Uta, Sramkova, Lucie, Zwaan, C. Michel, and Huitema, Alwin D.R.

Published
2024

10. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia:Results of Study ITCC-059

Author

Wu, Jen-Hao, Pennesi, Edoardo, Bautista, Francisco, Garrett, May, Fukuhara, Kei, Brivio, Erica, Ammerlaan, Anneke C. J., Locatelli, Franco, van der Sluis, Inge M., Rossig, Claudia, Chen-Santel, Christiane, Bielorai, Bella, Petit, Arnaud, Stary, Jan, Diaz-de-Heredia, Cristina, Rives, Susana, O'Marcaigh, Aengus, Rizzari, Carmelo, Engstler, Gernot, Nysom, Karsten, Rubio-San-Simon, Alba, Bruno, Benedicte, Bertrand, Yves, Brethon, Benoit, Rialland, Fanny, Plat, Genevieve, Dirksen, Uta, Sramkova, Lucie, Zwaan, C. Michel, Huitema, Alwin D. R., Wu, Jen-Hao, Pennesi, Edoardo, Bautista, Francisco, Garrett, May, Fukuhara, Kei, Brivio, Erica, Ammerlaan, Anneke C. J., Locatelli, Franco, van der Sluis, Inge M., Rossig, Claudia, Chen-Santel, Christiane, Bielorai, Bella, Petit, Arnaud, Stary, Jan, Diaz-de-Heredia, Cristina, Rives, Susana, O'Marcaigh, Aengus, Rizzari, Carmelo, Engstler, Gernot, Nysom, Karsten, Rubio-San-Simon, Alba, Bruno, Benedicte, Bertrand, Yves, Brethon, Benoit, Rialland, Fanny, Plat, Genevieve, Dirksen, Uta, Sramkova, Lucie, Zwaan, C. Michel, and Huitema, Alwin D. R.

Abstract

Background and Objective: Inotuzumab ozogamicin is an antibody-drug conjugate approved for treating relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in adults. Pediatric pharmacokinetic data of inotuzumab ozogamicin are lacking. This study is the first to examine the population pharmacokinetics of inotuzumab ozogamicin in pediatric patients with relapsed/refractory BCP-ALL. Methods: From 531 adult patients with B-cell non-Hodgkin’s lymphoma, 234 adult patients with BCP-ALL, and 53 pediatric patients with BCP-ALL, 8924 inotuzumab ozogamicin serum concentrations were analyzed using non-linear mixed-effects modeling. A published adult inotuzumab ozogamicin population-pharmacokinetic model, a two-compartment model with linear and time-dependent clearance, was adapted to describe the pediatric data. Results: Modifications in this analysis, compared to the published adult model, included: (i) re-estimating pharmacokinetic parameters and covariate effects; (ii) modifying covariate representation; and (iii) introducing relevant pediatric covariate effects (age on the decay coefficient of time-dependent clearance and ALL effect (disease type and/or different bioanalytical analysis methods) on initial values of time-dependent clearance). For patients with relapsed/refractory BCP-ALL, increasing age was associated with a decreasing decay coefficient of time-dependent clearance, reflecting that the target-mediated drug clearance declines more rapidly in children. In pediatric BCP-ALL, the median [interquartile range] cumulative area under the concentration–time curve was significantly higher among responders (n = 42) versus non-responders (n = 10) at the end of the first cycle (26.1 [18.9–35.0] vs 10.1 [9.19–16.1], × 10 3 ng*h/mL, p < 0.001). From simulations performed at the recommended pediatric phase II dose, inotuzumab ozogamicin exposure reached a similar level as observed in responding pediatric trial participants. Conclusions

Published
2024

13. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Author

Pennesi, Edoardo, primary, Brivio, Erica, additional, Ammerlaan, Anneke C. J., additional, Jiang, Yilin, additional, Van der Velden, Vincent H. J., additional, Beverloo, H. Berna, additional, Sleight, Barbara, additional, Locatelli, Franco, additional, Brethon, Benoit, additional, Rossig, Claudia, additional, Engstler, Gernot, additional, Nilsson, Anna, additional, Bruno, Benedicte, additional, Petit, Arnaud, additional, Bielorai, Bella, additional, Rizzari, Carmelo, additional, Rialland, Fanny, additional, Rubio-San-Simón, Alba, additional, Sirvent, Francisco J. Bautista, additional, Diaz-de-Heredia, Cristina, additional, Rives, Susana, additional, and Zwaan, Christian M., additional

Published
2024
Full Text
View/download PDF

15. Design Principle of Gene Expression Used by Human Stem Cells; Implication for Pluripotency

Author

Golan-Mashiach, Michal, Dazard, Jean-Eudes, Gerecht-Nir, Sharon, Amariglio, Ninette, Fisher, Tamar, Jacob-Hirsch, Jasmine, Bielorai, Bella, Osenberg, Sivan, Barad, Omer, Getz, Gad, Toren, Amos, Rechavi, Gideon, Eldor-Itskovitz, Joseph, Domany, Eytan, and Givol, David

Subjects
Quantitative Biology - Quantitative Methods, Quantitative Biology - Other Quantitative Biology
Abstract

Human embryonic stem cells (ESC) are undifferentiated and are endowed with the capacities of self renewal and pluripotential differentiation. Adult stem cells renew their own tissue, but whether they can trans-differentiate to other tissues is still controversial. To understand the genetic program that underlies the pluripotency of stem cells, we compared the transcription profile of ESC with that of progenitor/stem cells of human hematopoietic and keratinocytic origins, along with their mature cells to be viewed as snapshots along tissue differentiation. ESC gene profile show higher complexity with significantly more highly expressed genes than adult cells. We hypothesize that ESC use a strategy of expressing genes that represent various differentiation pathways and selection of only a few for continuous expression upon differentiation to a particular target. Such a strategy may be necessary for the pluripotency of ESC. The progenitors of either hematopoietic or keratinocytic cells also follow the same design principle. Using advanced clustering, we show that many of the ESC expressed genes are turned off in the progenitors/stem cells followed by a further downregulation in adult tissues. Concomitantly, genes specific to the target tissue are upregulated towards matured cells of skin or blood., Comment: To appear in FASEB Journal; 32 pages

Published
2004

21. Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes

Author

Jacoby, Elad, primary, Bar-Yosef, Omer, additional, Gruber, Noah, additional, Lahav, Einat, additional, Varda-Bloom, Nira, additional, Bolkier, Yoav, additional, Bar, Diana, additional, Blumkin, Moriya Ben-Yakir, additional, Barak, Sharon, additional, Eisenstein, Etzyona, additional, Ahonniska-Assa, Jaana, additional, Silberg, Tamar, additional, Krasovsky, Tal, additional, Bar, Orly, additional, Erez, Neta, additional, Bielorai, Bella, additional, Golan, Hana, additional, Dekel, Benjamin, additional, Besser, Michal J., additional, Pozner, Gat, additional, Khoury, Hanan, additional, Jacobs, Alan, additional, Campbell, John, additional, Herskovitz, Eli, additional, Sher, Noa, additional, Yivgi-Ohana, Natalie, additional, Anikster, Yair, additional, and Toren, Amos, additional

Published
2022
Full Text
View/download PDF

22. Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Author

Pennesi, Edoardo, primary, Brivio, Erica, additional, Ammerlaan, Anneke C.J., additional, Jiang, Yilin, additional, van der Velden, Vincent H.J., additional, Beverloo, Berna, additional, Sleight, Barbara, additional, Rives, Susana, additional, Díaz de Heredia Rubio, Cristina, additional, Bautista Sirvent, Francisco J., additional, Rubio-San-Simón, Alba, additional, Rialland, Fanny, additional, Rizzari, Carmelo, additional, Bielorai, Bella, additional, Petit, Arnaud, additional, Bruno, Bénédicte, additional, Øra, Ingrid, additional, Nilsson, Anna, additional, Engstler, Gernot, additional, Rossig, Claudia, additional, Brethon, Benoit, additional, Locatelli, Franco, additional, and Zwaan, Christian M., additional

Published
2022
Full Text
View/download PDF

23. Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Author

Pennesi, Edoardo, primary, Brivio, Erica, additional, Pelletier, Kathleen B., additional, Chen, Ying, additional, Huitema, Alwin D.R., additional, Jiang, Yilin, additional, Ammerlaan, Anneke C.J., additional, Sleight, Barbara, additional, Locatelli, Franco, additional, Van Der Sluis, Inge M., additional, Rossig, Claudia, additional, Chen-Santel, Christiane, additional, Bielorai, Bella, additional, Petit, Arnaud, additional, Stary, Jan, additional, Sramkova, Lucie, additional, Díaz de Heredia Rubio, Cristina, additional, Rives, Susana, additional, O'Marcaigh, Aengus, additional, Rizzari, Carmelo, additional, Engstler, Gernot, additional, Nysom, Karsten, additional, Rubio-San-Simón, Alba, additional, Bautista Sirvent, Francisco J., additional, Bruno, Bénédicte, additional, Bertrand, Yives, additional, Brethon, Benoit, additional, Rialland, Fanny, additional, Plat, Genevieve, additional, Dirksen, Uta, additional, Garrett, May, additional, and Zwaan, Christian M., additional

Published
2022
Full Text
View/download PDF

24. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens

Author

Bitan, Menachem, He, Wensheng, Zhang, Mei-Jie, Abdel-Azim, Hisham, Ayas, Mouhab Fakhreddine, Bielorai, Bella, Carpenter, Paul A., Cairo, Mitchell S., Diaz, Miguel Angel, Horan, John T., Jodele, Sonata, Kitko, Carrie L., Schultz, Kirk R., Kletzel, Morris, Kasow, Kimberly A., Lehmann, Leslie E., Mehta, Parinda A., Shah, Nirali, Pulsipher, Michael A., Prestidge, Tim, Seber, Adriana, Shenoy, Shalini, Woolfrey, Ann E., Yu, Lolie C., and Davies, Stella M.

Published
2014
Full Text
View/download PDF

26. αβ+/CD19+‐depleted haploidentical stem cell transplantation for children with acute leukemia: Is there a protective effect of increased γδ+ T‐cell content in the graft?

Author

Dadi, Gal, Jacoby, Elad, Adam, Etai, Hutt, Daphna, Varda‐Bloom, Nira, Bielorai, Bella, and Toren, Amos

Subjects
STEM cell transplantation, ACUTE leukemia, HEMATOPOIETIC stem cell transplantation, T cells, DISEASE remission, ACUTE diseases
Abstract

Background: Haploidentical hematopoietic stem cell transplantation (HSCT) with depletion of αβ+ T cells and CD19+ B cells has emerged as a viable alternative to traditional donors for treating acute leukemia in children. As the use of this innovative approach continues to grow and more experience is gained, it is essential to identify and comprehend the key factors that contribute to successful transplantation and improved outcomes. Methods: We conducted a retrospective analysis of single‐center data from 27 children with acute lymphoblastic leukemia and 11 children with acute myeloid leukemia who underwent haploidentical HSCT with depletion of αβ+ T cells and CD19+ B cells between the years 2013 and 2020. Results: Engraftment was successful in 34 out of 38 patients (90%). The 5‐year overall survival and event‐free survival rates were 51% and 42%, respectively. There were no cases of grade III–IV acute graft‐versus‐host disease, and only two patients developed chronic graft‐versus‐host disease. Patients with a higher content of γδ+ T cells in the graft demonstrated a longer event‐free survival. Conclusions: αβ+/CD19+‐depleted haploidentical hematopoietic stem cell transplantation can offer long‐term remission for children with acute leukemia with minimal graft‐versus‐host disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia:results from a phase II trial

Author

Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H.J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J.C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, Zwaan, Christian M., Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H.J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J.C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, and Zwaan, Christian M.

Abstract

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1–18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using a single-stage design, with an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% as expected, 25 patients needed to be recruited to achieve 80% power at 0.05 significance level. Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated ORR was 81.5% (95%CI: 61.9–93.7%), and 81.8% (18/22) of the responding subjects were minimal residual disease (MRD) negative. The study met its primary endpoint. Median follow up of survivors was 16 months (IQR: 14.49–20.07). One year Event Free Survival was 36.7% (95% CI: 22.2–60.4%), and Overall Survival was 55.1% (95% CI: 39.1−77.7%). Eighteen patients received consolidation (with HSCT and/or CAR T-cells therapy). Sinusoidal obstructive syndrome (SOS) occurred in seven patients. MRD negativity seemed correlated to calicheamicin sensitivity in vitro, but not to CD22 surface expression, saturation, or internalization. InO was effective in this population. The most relevant risk was the occurrence of SOS, particularly when InO treatment was followed by HSCT.

Published
2022

31. Invasive Fusariosis in Pediatric Hematology/Oncology and Stem Cell Transplant Patients: A Report from the Israeli Society of Pediatric Hematology-Oncology

Author

Benish, Marganit, primary, Elitzur, Sarah, additional, Arad-Cohen, Nira, additional, Barg, Assaf Arie, additional, Ben-Harosh, Miriam, additional, Bielorai, Bella, additional, Fischer, Salvador, additional, Gilad, Gil, additional, Levy, Itzhak, additional, Rosenfeld-Keidar, Hila, additional, Shachor-Meyouhas, Yael, additional, Soen-Grisaru, Galia, additional, Weinreb, Sigal, additional, Nirel, Ronit, additional, and Elhasid, Ronit, additional

Published
2022
Full Text
View/download PDF

39. Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Author

Jacoby, Elad, primary, Ghorashian, Sara, additional, Vormoor, Britta Julia, additional, De Moerloose, Barbara, additional, Bodmer, Nicole, additional, Maschan, Michael, additional, Yanir, Asaf David, additional, Bielorai, Bella, additional, Rogosic, Srdan, additional, Molostova, Olga, additional, Rossig, Claudia, additional, Toren, Amos, additional, von Stackelberg, Arend, additional, and Bourquin, Jean-Pierre, additional

Published
2020
Full Text
View/download PDF

40. A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Author

Brivio, Erica, primary, Locatelli, Franco, additional, Thano, Adriana, additional, Petit, Arnaud, additional, Vormoor, Britta Julia, additional, Rives, Susana, additional, Bielorai, Bella, additional, Rossig, Claudia, additional, Rizzari, Carmelo, additional, Van Der Velden, Vincent H.J., additional, Ammerlaan, Anneke C.J., additional, Den Boer, Monique L., additional, Sleight, Barbara, additional, Engstler, Gernot, additional, Stary, Jan, additional, Bautista Sirvent, Francisco José, additional, Chen-Santel, Christiane, additional, Bruno, Bénédicte, additional, Bertrand, Yves, additional, Rialland, Fanny, additional, Plat, Geneviève, additional, Reinhardt, Dirk, additional, Vinti, Luciana, additional, von Stackelberg, Arend, additional, and Zwaan, Christian Michel, additional

Published
2020
Full Text
View/download PDF

41. Venous Thromboembolism and Its Risk Factors in Children with Acute Lymphoblastic Leukemia in Israel: A Population-Based Study

Author

Barzilai-Birenboim, Shlomit, primary, Nirel, Ronit, additional, Arad-Cohen, Nira, additional, Avrahami, Galia, additional, Ben Harush, Miri, additional, Barg, Assaf, additional, Bielorai, Bella, additional, Elhasid, Ronit, additional, Gilad, Gil, additional, Toren, Amos, additional, Weinreb, Sigal, additional, Izraeli, Shai, additional, and Elitzur, Sarah, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results